MetaCap

Intellia Therapeutics Inc. (NTLA)

NASDAQ: NTLAHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD

10.00+0.48 (+5.04%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

NTLA stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$3.35
52-week range
8.09 – 18.48
Day range
9.30 – 10.40
Volume / Avg
15.18M / 5.03M
Beta
—

52-week range

$8.09$18.48

NTLA stock today

On Nov 20, NTLA ended the session at $10.00, adding $0.48 (5.04%), versus the S&P 500's 3.70% decline. Volume was 3.0x the average at 15.18M shares, a sign of unusually heavy trading. Shares are 45.9% below their 52-week high of $18.48, set on Jul 2, 2026 and 23.7% above the 52-week low of $8.09, near the bottom of the past year's range.

NTLA is up 11.2% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 21.8%. Intellia Therapeutics has posted a net loss over the last twelve months (EPS of -$3.35), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Intellia Therapeutics

Company profile

Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (“CRISPR”)/CRISPR associated 9 (“Cas9”) technology for genome editing.

Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
CEO
Dr. John M. Leonard M.D.
Headquarters
Cambridge, MA
Employees
377
IPO year
2016

Financial highlights

Full financials

In fiscal 2025, Intellia Therapeutics generated $67.7 million in revenue, up 16.9% from fiscal 2024, its 2nd consecutive year of revenue growth. Intellia Therapeutics reported a net loss of $412.7 million, compared with a loss of $519.0 million a year earlier. Operating margin was -651.7%.

Intellia Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$67.67M$57.88M$36.27M$52.12M$33.05M
Growth+16.92%+59.55%-30.40%+57.69%-43.01%
Net income$-412.69M$-519.02M$-481.19M$-474.19M$-267.89M
EPS (diluted)$-3.81$-5.25$-5.42$-6.16$-3.78

Analyst forecast

Forecast

Consensus (20 analysts)

buy

Avg. price target

$22.78+127.80%

  • Strong buy 1
  • Buy 9
  • Hold 6
  • Sell 2
  • Strong sell 2

Target range

Low $8.00High $61.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-0.91 vs $-0.82
Surprise
-10.98%

NTLA news

All NTLA news

Intellia Therapeutics peers

Health Care sector
NTLA peer companies
CompanyPrice% ChgMarket capCompare
CLDXCelldex Therapeutics Inc.27.42-1.93%$2.15Bvs NTLA
QUITAchieve Life Sciences Inc.5.56-5.28%$573.25Mvs NTLA
QDELQuidelOrtho Corporation8.32-6.73%$570.86Mvs NTLA
MYGNMyriad Genetics Inc.5.46-1.44%$523.74Mvs NTLA
NEOGNeogen Corporation10.55-2.77%$2.30Bvs NTLA
TKNOAlpha Teknova Inc.7.63-2.30%$479.95Mvs NTLA
NNNNAnbio Biotechnology Class A3.32-9.04%$145.72Mvs NTLA
ICCCImmuCell Corporation10.92-2.41%$99.28Mvs NTLA

Indexes, lists and sector

Intellia Therapeutics stock FAQ

What is Intellia Therapeutics's stock price today?

NTLA last traded at $10.00 as of Nov 20, 4:00 PM EST, up 5.04% on the day. Prices are delayed at least 15 minutes.

Who is Intellia Therapeutics's CEO?

Dr. John M. Leonard M.D. is the chief executive officer of Intellia Therapeutics Inc., which has about 377 employees.

What is the NTLA 52-week high?

The 52-week high for NTLA is $18.48 and the 52-week low is $8.09. The stock is currently 45.9% below its high.

Compare NTLA